{
    "nct_id": "NCT04030195",
    "official_title": "A Phase 1/2a, Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate the Safety and Clinical Activity of PBCAR20A in Subjects With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) or r/r Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)",
    "inclusion_criteria": "Healthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "Criteria for NHL:\n\n* Requirement for urgent therapy due to mass effects such as bowel obstruction, spinal cord, or blood vessel compression.\n* Active central nervous system (CNS) disease. A negative computed tomography (CT)/magnetic resonance imaging (MRI) is required at Screening if the study participant has a history of CNS lymphoma.\n\nCriteria for NHL and CLL/SLL:\n\n* Active CNS disease. A negative lumbar puncture is required at Screening if the study participant has a history of CNS disease.\n* Previous malignancy, besides the malignancies of inclusion (B-cell NHL or CLL/SLL), that in the investigator's opinion, has a high risk of relapse in the next 2 years.\n* Active uncontrolled fungal, bacterial, viral, protozoal, or other infection.\n* Any form of primary immunodeficiency.\n* History of human immunodeficiency virus (HIV) infection.\n* Active hepatitis B or C.\n* Uncontrolled cardiovascular disease.\n* Hypertension crisis or hypertensive encephalopathy within 3 months prior to Screening.\n* Presence of a CNS disorder that renders ineligible for treatment.\n* History of a genetic syndrome such as Fanconi anemia, Kostmann syndrome, Shwachman Diamond syndrome, or any other known bone marrow failure syndrome.\n* Received ASCT within 45 days of Screening if the study participant has met the rest of the count requirements.\n* Must not have received systemic corticosteroid therapy for at least 7 days prior to initiating lymphodepletion chemotherapy.\n* Received a live vaccine within 4 weeks before Screening.\n* Radiotherapy within 4 weeks determined on a case-by-case basis.\n* Presence of a pleural/peritoneal/pericardial catheter.\n* Current use of any anticoagulant or antiplatelet therapy.",
    "miscellaneous_criteria": "Key Inclusion Criteria\n\nCriteria for NHL:\n\n* r/r CD20+ B-cell NHL that is histologically confirmed by archived tumor biopsy tissue from the last relapse and corresponding pathology report.\n* Measurable or detectable disease according to the Lugano classification.\n* Primary refractory disease or r/r disease after a response to 2 prior regimens.\n\nCriteria for CLL/SLL:\n\n* Diagnosis of CD20+ CLL with indication for treatment based on the iwCLL guidelines and clinically measurable disease or SLL with measurable disease that is biopsy-proven SLL.\n* Previously failed/tolerant to at least 2 prior lines of systemic targeted therapy of known benefit.\n\nCriteria for both NHL and CLL/SLL:\n\n* Study participant has an Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.\n* Study participant has adequate bone marrow, renal, hepatic, pulmonary, and cardiac function.\n\nKey"
}